Replies to post #100820 on Biotech Values

[oc631]

Do you recall if it was the same analyst?

[Mpower]

Interesting that the Bernstein analyst had no note about Generic Copaxone. Well, at least this explains the "weakness" of the past few days. I look forwad to the reversal.

[pollyvonwog]

The bogus Bernstein report in January caused MNTA’s share price to run up substantially, which probably enabled a Bernstein client (or the firm itself) to cash out at a better price.

I think it is fair to say something of a similar nature has occured here... The large PUT action before this was released all makes sense now...

[rkrw]

To be fair MNTA was approved in 6-months, which after waiting 5 years isn't far off imminent.

Was nvs setting prices and soliciting pre orders?

[DewDiligence]

FWIW, I added MNTA shares today at 17.99-18.05.

As some other posters have already posted, MNTA’s current valuation entirely or almost entirely discounts a Teva generic entering the market in the near future.

[DewDiligence]

The effect of Bernstein’s bogus rumor/report on Lovenox may have run its course.

[DewDiligence]

Sanford Bernstein’s Tim Anderson is at it again; he’s now touting the notion that PFE will sell off “non-core” businesses. This is hardly an original idea, but Anderson is dead wrong, IMO, about PFE’s plans for its so-called Established Products division:

http://online.wsj.com/article/BT-CO-20110314-708734.html

Anderson sees the potential for Pfizer to spin off five of its nine distinct business units: animal health, consumer health, nutritionals, Capsugel, and established products. The biggest unit would be Pfizer's established-products division, which includes generic drugs. Anderson said this unit generated sales of $10 billion for 2010, but probably would grow to $17 billion in coming years when Lipitor and other products lose patent protection.

He doesn’t get it—PFE’s Established Products division is the vanguard of the global pharmaceutical industry, as detailed in #msg-59590951.

Anderson gets my vote for the honor of least trustworthy drug/biotech analyst on Wall Street. For those who may have forgotten, Anderson is the analyst who trumpeted in Aug 2010 that Teva’s Lovenox approval was imminent (#msg-52999229).